Clinical Effects of Standard and Individualized Dialysate Sodium in Patients on Maintenance Hemodialysis by Eftimovskaâ€“Otovic, Natasa et al.
  
_______________________________________________________________________________________________________________________________ 
  248                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
ID Design 2012/DOOEL Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2016 Jun 15; 4(2):248-252. 
http://dx.doi.org/10.3889/oamjms.2016.056 
eISSN: 1857-9655 
Clinical Science 
  
 
 
 
Clinical Effects of Standard and Individualized Dialysate Sodium 
in Patients on Maintenance Hemodialysis 
 
 
Natasa Eftimovska–Otovic
1*
, Olivera Stojceva-Taneva
2
, Risto Grozdanovski
1
, Saso Stojcev
3
 
  
1
Specialized Hospital for Nephrology and Dialysis “Diamed”, Skopje, Republic of Macedonia; 
2
University Clinic for 
Nephrology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 
3
General City 
Hospital “8th September”, Skopje, Republic of Macedonia 
 
 
Citation: Eftimovska–Otovic N, Stojceva-Taneva O, 
Grozdanovski R, Stojcev S. Clinical Effects of Standard 
and Individualized Dialysate Sodium in Patients on 
Maintenance Hemodialysis. Open Access Maced J Med 
Sci. 2016 Jun 15; 4(2):248-252. 
http://dx.doi.org/10.3889/oamjms.2016.056 
Key words: blood pressure; thirst; dialysate sodium; 
hemodialysis. 
*Correspondence: Dr. Natasa Eftimovska – Otovic. 
Gjorce Petrov 23, 1000, Skopje, E-mail: 
neftimovska@yahoo.com  
Received: 10-Mar-2016; Revised: 28-Apr-2016; 
Accepted: 29-Apr-2016; Online first: 10-May-2016 
Copyright: © 2016 Natasa Eftimovska–Otovic, Olivera 
Stojceva-Taneva, Risto Grozdanovski, Saso Stojcev. This 
is an open access article distributed under the terms of 
the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are 
credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract  
BACKGROUND: The degree to which the dialysate prescription and, in particular, the dialysate 
sodium concentration influences blood pressure and interdialytic weight gain (IDWG) via changes in 
sodium flux, plasma volume or the other parameters is not well understood. The aim of the study 
was to investigate whether dialysis patients will have some beneficial effects of dialysate sodium 
set up according to serum sodium or sodium modeling. 
MATERIAL AND METHODS: Ninety-two nondiabetic subjects (52 men and 40 women) performed 
12 consecutive hemodialysis (HD) sessions (4 weeks) with dialysate sodium concentration set up 
on 138 mmol/L (standard sodium – first phase), followed by 24 sessions (second phase) wherein 
dialysate sodium was set up according to individualized sodium. Variables of interest were: systolic, 
diastolic and mean blood pressure, pulse, IDWG, thirst score – (Xerostomia Inventory (XI) and 
Dialysis Thirst Inventory (DTI)) and side effects (occurrence of hypotension and muscle cramps). 
After the first phase, the subjects were divided into 3 groups: normotensive (N=76), hypertensive 
(N= 11) and hypotensive (N=5) based on the average pre-HD systolic BP during the whole period 
of the first phase. 
RESULTS: Sodium individualization resulted in significantly lower blood pressure (133.61 ± 11.88 
versus 153.60 ± 14.26 mmHg; p=0.000) and IDWG (2.21 ± 0.93 versus 1.87 ± 0.92 kg; p=0.018) in 
hypertensive patients, whereas normotensive patients showed only significant decrease in IDWG 
(2.21 ± 0.72 versus 2.06 ± 0.65, p=0,004). Sodium profiling in hypotensive patients significantly 
increased IDWG (2.45 vs. 2.74, p= 0,006), and had no impact on blood pressure. Thirst score was 
significantly lower in normotensive patients with individualized-sodium HD and showed no change 
in the other two groups. During the second phase, hypotension occurred in only 1 case and muscle 
cramps in 10 normotensive patients. 
CONCLUSION: Individualized sodium resulted in clinical benefits in normotensive and hypertensive 
patients.  
 
 
 
Introduction 
 
Prescription of dialysate sodium for patients 
on maintenance hemodialysis remains still unclear 
and not enough investigated issue. During the first 
years when dialysis was introduced as a renal 
replacement therapy for patients with end-stage renal 
failure, dialysate sodium prescription was 126.5 
mmol/l. Before introduction of volumetric controlled 
ultrafiltration, sodium was removed primarily, slowly 
and most predictably by diffusion. With the 
development of high flux dialysis membranes, 
dialysate osmolality asserted a faster and more 
dramatic effect on serum osmolality. Hypotonic 
dialysate rapidly drops serum osmolality that leads to 
net fluid shift out of the vascular space, causing 
significant intradialytic symptoms. Furthermore, the 
duration of dialysis sessions was shortened as 
clearance of urea was improved, requiring an 
accelerated rate of ultrafiltration. To counter 
symptoms of hypo-osmolarity and rapid ultrafiltration, 
dialysate sodium concentration was increased to level 
of 140 mmol/L and higher just to maintain 
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hemodynamic stability during dialysis and to avoid 
side effects of dialysis – disequilibrium. This was 
followed by a loss of control of extracellular volume 
(ECV) and blood pressure (BP) [1]. This led a lot of 
studies to investigate on which level the dialysate 
sodium should be set up. Current hemodialysis (HD) 
practices adopt a standard dialysate sodium 
prescription that is typically higher than the plasma 
sodium concentration of most patients. However, 
hypertonic dialysate sodium prescriptions, including 
sodium modeling, predispose to positive sodium 
balance and lead to higher BP and increased 
interdialytic weight gain [2]. Predialysis plasma 
sodium concentration is constant in HD patients, and 
these patients seem to have an individual osmolar set 
point with a small variances of 1-2% and this is the 
value on which dialysate sodium should be prescribed 
to eliminate the interdialytic accumulated sodium 
mainly by convection [3]. On the other hand, lowering 
or individualizing dialysate sodium aims to reduce 
thirst, IDWG and BP in non-hypotensive prone 
patients [4]. In hypotensive-prone patients, dialysate 
sodium modeling is very ofen used (start of HD with 
higher dialysate sodium and slowly lowering during 
the session to standrad sodium, mostly to 138 
mmol/L) to keep hemodynamic stability. In 
approximately 10%–15% of patients, instead of 
decreasing, BP paradoxically increases during 
dialysis. These patients have intradialytic 
hypertension [5]. The degree to which the dialysate 
prescription and, in particular, the dialysate sodium 
concentration influences blood pressure and IDWG 
via changes in sodium flux, plasma volume or the 
other parameters is not well understood. The aim of 
the study was to investigate whether dialysis patients 
will have some beneficial effects of dialysate sodium 
set up according to serum sodium or sodium 
modeling. 
 
 
Materials and Methods 
 
The study was carried out in a single dialysis 
center treating 109 patients with maintenance 
hemodialysis. It was performed in two different 
phases, with each subject used as own control. Dry 
weight, dialysis prescription and medications were not 
modified during the study, except for dialysate sodium 
concentration. Blood flow was in general 250 ml/min, 
and increased in some patients up to 290 ml/min, and 
dialysate flow was 500 ml/min, up to 550 ml/min in 
some patients. Out of 109 treated in our center, the 
study included 92 non-diabetic subjects on high flux 
bicarbonate dialysis, 3 times weekly and residual 
diuresis below 300 ml/day. Before the start of the 
study, the average pre-HD plasma sodium 
concentration was calculated (mean value of 12 
monthly measurements). During the first phase, the 
patients underwent 12 consecutive HD sessions (4 
weeks) with dialysate sodium concentration set up on 
138 mmol/L (which accounts for a standard sodium 
concentration in our center). During the second 
phase, the patients underwent 24 HD sessions (8 
weeks) wherein dialysate sodium was set to the mean 
value of the pre – HD plasma sodium concentration of 
each individual patient (individualized sodium). 
Patients were not aware of the modification in the 
dialysate sodium concentration.  
Pre-, intra-and post-HD blood pressure were 
measured using Omron M6 comfort device. After the 
first phase, the subjects were divided into 3 groups: 
normotensive (N = 76), hypertensive (N = 11) and 
hypotensive (N = 5) based on the average pre-HD 
systolic BP during the whole period of the first phase. 
Hypertensive patients were defined as pre-HD systolic 
BP >/= 140 mmHg or an increase of more than 10 
mmHg during or at the end of the session, while 
hypotensive patients were defined as pre-HD systolic 
BP </=90 mmHg or having a drop in BP of more than 
10 mmHg during or at the end of the session [5]. 
According to the NKF k-DOQI guidelines, predialysis 
and postdialysis blood pressure goals should be 
<140/90 mmHg and <130/80 mmHg, respectively [6]. 
After the first phase, hypotensive-prone patients 
underwent dialysis with sodium modeling (145-138 
mmol/L) and the other two groups underwent dialysis 
with individualized sodium. Variables of interest were: 
systolic, diastolic and mean blood pressure, pulse, 
IDWG, thirst score and side effects (episodes of 
hypotension and muscle cramps). Interdialytic fluid 
accumulation was derived from the difference in 
weight before next hemodialysis and weight at the end 
of the previous hemodialysis. Mean blood pressure 
was calculated as the sum of the systolic plus doubled 
diastolic pressure, divided by three. Thirst was 
assessed using two different scales: Xerostomia 
Inventory (XI) and Dialysis Thirst Inventory (DTI) [7].  
The sodium was measured with direct ion 
selective method. This method measures non-
complexed, free sodium concentration in plasma 
water, which represents those sodium molecules 
available for diffusion. If the patient was prescribed 
sodium modeling, we calculated the sodium gradient 
as the difference between the dialysate sodium 
averaged concentration and the pre-HD plasma 
sodium in the previous 12 months. 
The adequacy of dialysis (spKt/V) was 
estimated by the Daugirdas equation [8].  
Statistical analysis was performed using the 
statistical package SPSS Statistics 17. The results 
were expressed as mean (± SD). We used paired 
Student t-test to compare continuous variables 
between each study phase (the parameters of the 
total patient group were compared between the first 
and the second phase) and unpaired Student t-test 
was used to compare hypertensive with 
normostensive subjects. Pearson correlation 
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coeficient was used to study relationship between 
different continuous variables. P-values <0.05 were 
considered statistically significant.  
 
 
Results 
 
Ninety-two non-diabetic patients, 52 men and 
40 women with dialysis vintage 78.91 ± 67.52 months 
were analyzed. There were no statistical significant 
differences in SBP, DBP, MAP and pulse for all the 
subjects when compared with standard sodium 
dialysate and individualized sodium dialyzate. There 
was only significant decrease in pulse, IDWG, XI and 
DTI score in the inidividualized sodium dialysate 
group (Table 1).  
Table 1: Comparison of variables between standard-NaHD and 
individualized-Na HD 
Variables  Standard sodium Individualized sodium p-value 
SBP (mmHg) 124.99 ± 19.42 123.26 ± 15.77 0.128 
DBP (mmHg) 74.14 ± 10.87 73.20 ± 9.72 0.095 
MAP (mmHg) 87.67 ± 10.65 87.50 ± 11.08 0.759 
Pulse (beats/min) 78.54 ± 20.54 73.18 ± 11.58 0.000* 
IDWG (кg) 2.22 ± 0.73 2.08 ± 0.70 0.001* 
Xerostomia Inventory 
score 
17.77 ± 7.13 15.02 ± 5.59 0.000* 
Dialysis Thirst 
Inventory score 
12.70 ± 4.96 10.88 ± 4.28 0.000* 
 
However, when the patients were categorized 
into three goups, patients with hypertension, 
hypotension-prone patients and normotensive 
patients, it became apparent that hypertensive 
patients hada significant reduction in SBP (133.61 ± 
11.88 versus 153.60 ± 14.26 mm Hg; p = 0.000) 
during the individualized-sodium dialysis compared to 
standard-dialysate sodium, DBP (78.61 ± 4.73 versus 
87.85 ± 6.08 mmHg; p = 0.000) and MAP (96.94 ± 
5.95 versus 124.21 ± 23.80 mmHg; p = 0.008), 
whereas normotensive patients had a net, statistically 
not significant, increase in SBP, DBP and MAP. 
Statistical significant decrease in pulse was observed 
in normotensive patients, but not in hypertensive 
ones. During dialysis performed with standard-
dialysate sodium, normotensive and hypertensive 
patients had similar IDWG (2.21 ± 0.72 kg and 2.21 ± 
0.93 kg, respectively) which significantly decreased 
duringdialysis using individualized-sodium dialysate in 
both groups (2.06 ± 0.65 kg; p = 0.004 and 1.87 ± 
0.92 kg; p = 0.018, respectively). Assessment of thirst 
showed statistical significant decrease in 
normotensive patients when standard sodium dialysis 
was compared to individualized-sodium dialysis (XI 
score 17.94 ± 6.83 versus 15.00 ± 5.60; p=0.000 and 
DTI score 12.60 ± 4.71 versus 10.53 ± 4.08; p= 
0.000), whereas this difference was not stiatistically 
significant in hypertensive ones (XI score 18.00 ± 
10.19 versus 13.45 ± 5.59; p = 0.817 and DTI score 
11.90 ± 5.88 versus 10.27 ± 3.49; P = 0.118) (Table 
2). 
Table 2: Comparison of variables between standard-Na HD and 
individualized-Na HD in the three groups of patients 
(normotensive, hypertensive and hypotensive-prone patients) 
Variables  Normotensive N=76 Hypertensive N=11 
 
Hypotensive N=5 
Age 60.46±13.15 58.72±7.41 60.50±4.41 
sNa 
(mmol/L) 
136.77±1.47 1 136.36±0.24 1 136.66±1.50 
dNa Standard 
Na 
Individualized 
Na 
Standard 
Na 
Individualized 
Na 
Standard 
Na 
Profiling 
145-138 
Sodium 
gradient 
(mmol/L) 
1.21±1.49 // 1.63±0.80 // // // 
SBP  123.46±13.86 123.92±13.51 153.60±14.26 133.61±11.881 86.94±5.63 89.63±5.67 
DBP  73.55±8.89 73.61±9.16 87.85 ±6.08 78.61±4.73 1 54.05±2.32 55.02±2.07 
MAP  90.18±9.53 90.38±9.68 124.21±23.80 96.94±5.95 3 67.81±5.30 68.88±4.70 
Pulse  72.79±8.75 70.04±7.42 1 74.74±6.25 72.91±6.15 76.79±3.55 74.05±2.77 
IDWG  2.21±0.72 2.06±0.65 2 2.21±0.93 1.87±0.92 4 2.45±0.17 2.74±0.19 
5 
XI score  17.94±6.83 15.00±5.60 1 18.00 ±10.19 13.45±5.59 17.33±3.72 19.00±4.14 
DTI score  12.60±4.71 10.53±-4.08 1 11.90±5.88 10.27±3.49 16.00±5.89 17.00±4.00 
Sp Kt/V 1.49±0.27 1.50±0.24 1.42± 0.30 1.43±0.19 1.53±0.16 1.58±0.24 
P
1
= 0.000; p
2
 = 0.004; p
3 
= 0.008; p
4
 =0.018; p
5
 = 0.006. 
 
Plasma sodium concentration in all three 
groups of patients was close to 136 mmol/l, with 
positive sodium gradient in normotensive and 
hypertensive patients during the first phase. 
Hypertensive patients had higher positive sodium 
gradient in comparison to normotensive patients.In the 
individualized phase of the study, there was no 
sodium gradient.  
When the mean values of the variables in the 
individualized-Na HD were compared between the 
normotensive and hypertensive group of patients, 
statistically significant differences were observed in 
SBP, DBP, MAP, pusle, IDWG and sodium gradient 
(Table 3). 
Table 3: Comparison of the mean values of variables between 
the normostensive and hypertensive group of patients 
Variables  Normotensive patients 
 
Hypertensive patients 
 
p-value 
 
SBP (mmHg) 123.92 ± 13.51 133.61 ± 11.88 0.001 
DBP(mmHg) 73.61 ± 9.16 78.61 ± 4.73 0.001 
MAP(mmHg) 90.38 ± 9.68 96.94 ± 5.95 0.001 
Pulse (beats/min) 70.04 ± 7.42 72.91 ± 6.15 0.857 
IDWG (kg) 2.06 ± 0.65 1.87 ± 0.92 0.001 
Xerostomia Inventory 
score 
15.00 ± 5.60 13.45 ± 5.59 0.841 
Dialysis Thirst 
Inventory score 
10.53 ± 4.08 10.27 ± 3.49 0.695 
Sodium gradient  
(mmol/L) 
1.21 ± 1.49 1.62 ± 0.80 0.000 
 
The correlation between IDWG and the 
sodium gradient between dialysate-sodium and 
plasma-sodium concentration in the standard-sodium 
dialysis phase of the study showed statistical 
significance (r = 0.252; p = 0.019).But, there was no 
significant correlation between the sodium gradient 
and blood pressure in patients as a whole group, as 
well as in hypertensive patients only. During the 
individualized-sodium dialysis phase, we observed 
only 1 hypotensive occurrence and 3 appearances of 
muscle cramps in the normotensive group, whereas 
all the other patients remained asymptomatic. 
The hypotensive group of patients underwent 
dialysis with sodium modeling of 145-138 mmol/L. 
But, nevertheless, we still observed an increase in 
SBP when we compared it to standard-sodium 
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dialysis (89.63 ± 5.67 versus 86.94 ± 5.63 mm Hg; p = 
0.352), DBP (55.02 ± 2.07 versus 54.05 ± 2.32 mm 
Hg; p = 0.623) and MAP (68.88 ± 4.70 versus 67.81 ± 
5.30 mm Hg; p = 0.859) although statistically not 
significant. There was a statistically significant 
increase in IDWG compared to standard-dialysate 
sodium (2.74 ± 0.19 kg versus 2.45 ± 0.17 kg; p = 
0.006). The thirst score didn’t show statistically 
significant differencewhen compared to standard- 
sodium dialysis (XI 19.00 ± 4.14 versus 17.33 ± 3.72; 
p = 0.459 and DTI 17.00 ± 4.00 versus 16.00 ± 5.89; p 
= 0.141). 
 
 
Discussion 
 
Our study analyzed the short – term 
consequences (BP, IDWG and subjective feeling of 
thirst) of an individualized-sodium and sodium-
modeling prescription dialysis in non-diabetic HD 
patients. The short-term duration of the study allowed 
other important parameters to remain unchanged, 
such as dry weight and antihypertensive medications. 
The most prescribed antihypertensive drugs were: 
angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers and calcium channel blockers. The 
main findings in our study were reduction in IDWG 
and improvement in predialysis BP in hypertensive 
patients.  
When the patients were analyzed as a whole 
group, we didn’t find significant differences in BP, 
IDWG and thirst score when standard-Na HD was 
compared to individualized-Na HD. The same 
conclusion is reported by De Paulaet all [9]. In our 
study, the sodium gradient was significantly higher in 
hypertensive compared to normotensive patients, 
suggesting lower values of pre-HD plasma sodium 
concentration in patients with poorly controlled BP and 
higher sodium overload during the dialysis, causing 
thirst and volume overload. Bylinear regression 
analyses, Keen and Gotch and Mendoza et all. 
showed a statistically significant association between 
the magnitude of the Na+ gradient and interdialytic 
weight gain and blood pressurein smaller samples of 
HD patients [10, 11]. But, Heckinget all, reported that 
higher dialysate-Na prescriptions are associated with 
increased IDWG, but not with a higher risk for 
hospitalization or death. Instead, patients dialyzed 
with higher dialysate-Na concentrations had a 
significantly lower risk for hospitalization and, in 
facilities where all or almost all patients used the 
same dialysate-Na, a significantly lower risk for death 
[12]. Individualizing the dialysate-sodium is a simple 
complementary strategy to restrict sodium in HD that 
may help reduce IDWG in some patients [13, 14]. In 
our study, we did not find a direct correlation between 
the sodium gradient and BP, which was confirmed by 
other investigators, too [11]. This might be a result of 
the use of antihypertensive agents, which may mask 
such correlation.  
After categorizing the patients into three 
groups,it appeared that hypertensive patients had 
statistically significant decrease in BP compared to 
normotensive patients. The drop of BP appeared very 
soon, after changing thedialysate sodium, which 
overcame the “lag period” reported in the world 
literature [15]. This drop was probably a result of a 
better sodium balance and lower peripheral vascular 
resistance. We, also, found a significant decrease in 
IDWG in normotensive and hypertensive patients 
during the individualized-Na HD, suggesting no 
sodium overload during HD, which otherwise, forces 
the patient to drink more in order to bring own 
osmolarity back to its “set point”. This was also 
confirmedin hypotensive-prone patients who were 
dialysed with sodium modeling. Even though ending 
the dialysis session with a dialysate-Na of 138 
mmol/L, these patients most probably had sodium 
overload during their HD, which led them to 
interdialytic fluid intake (IDWG 2.74 ± 0.19 kg in 
profiling Na vs. 2.45 ± 0.17 kg in standard-Na; p = 
0.006). Sodium overload during sodium modeling was 
reported by Oliver and Lam, too [16, 17]. Hypotensive 
patients in our study did not have increased thirst, 
probably as a result of their regularsalt and fluid 
intakeaiming to increase their BP at home.  
Individualization of dialysate-Na was very well 
tolerated by patients, probably as a result of the lower 
IDWG and lower UF rate, with almost no adverse 
events (one case of hypotension and few cases with 
muscle cramps). But, on the other hand, aiming to 
reach eunatremia may increase the risk of intradialytic 
hypotension. Indeed, two studies reported a reduction 
in the frequency of intradialytic hypotension after 
decreasing dialysate sodium [9, 18]. Therefore, 
individualization of dialysate sodium mainly influences 
the IDWG and leads to better BP control in patients 
with poorly controlled BP and this group of patients is 
generally asymptomatic.On the other hand, this is not 
the case with hemodiynamically stable patients or 
hypotensive-prone patients, where individualization of 
dialysate sodium has no influence on BP. The sodium 
modeling in our patients, too, did not result in better 
BP control (patients had the usual drop in BP) and led 
to increase in IDWG requiring higher UF rate which 
consequently, favors occurrence of hypotension. The 
results of some studies also suggest that the sodium 
profiling method does not prevent the increase in 
interdialytic weight gain and thirst often seen with 
other forms of high-sodium dialysis, and probably 
does not reduce the incidence of side effects [10, 19]. 
Analysis of the subjective feeling of thirst 
showed only a significant decrease in the thirst score 
in the normotensive group of patients, with no 
influence in the hypertensive and hypotensive group. 
Our speculation is that this is a result of the good 
nutrition status of patients, accompanied by sufficient 
intake of fats and calories as well as water, and we 
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also agree with Lindey who postulated that patients 
drink fluids due to non –salt related reasons, such as 
comfort, social drinking or personal convictions [20, 
21]. 
The study had few limitations: BP was not 
measured in the interdialytic period and sodium 
balance was not assessed during dialysis. 
Furthermore, the number of patients in the compared 
groups (normo-, hyper- and hypotensive) was not 
consistent and balanced, since all the patients 
included in the study belonged to one dialysis center 
and it was not possible to increase their number. 
These results impose the need for additional study 
including more patients from multiple dialysis centers.  
In conclusion, the optimal dialysate sodium is 
not well defined and it dependson clinical 
circumstances. In hypertensive and stable 
normotensive patients isonatremic dialysis, or dialysis 
with lower dialysate sodium should be performed. 
Higher dialysate sodium in stable patients and sodium 
modeling in hipotensive-prone patients increases 
IDWG, but has no influence on blood pressure, 
suggesting that some other factors are involved that 
require further investigations. In these groups of 
patients we suggest the ultrafiltrate sodium 
concentration to be used as a dialysate-sodium 
prescription for future investigations.  
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